Study identification

EU PAS number

EUPAS1000000376

Study ID

1000000376

Official title and acronym

Effectiveness of Pfizer-BioNTech COVID-19 mRNA vaccine against severe illness in the elderly in Finland (RWE_COVID19_2023)

DARWIN EU® study

No

Study countries

Finland

Study description

The objective is to study the effectiveness of Pfizer-BioNTech COVID-19 mRNA vaccine against severe COVID-19 disease in the elderly by using real-world data collected in population-based national health registers in Finland.

Study status

Ongoing
Research institutions and networks

Institutions

FVR – Finnish Vaccine Research
Finland
First published:
15/11/2024
Institution Hospital/Clinic/Other health care facility Laboratory/Research/Testing facility

Contact details

Arto Palmu

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual:

Study start date

Actual:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Pfizer Inc.
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable